Health Condition 1: B954- Other streptococcus as the cause of diseases classified elsewhere
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adult male or female subjects (age 18-60yrs) 2.Subjects with at least 24 teeth. 3.Subjects having gingival probing depth of less than 3mm. 4.Subjects having gingival index scores equal to 2 and in more than 10% of the sites. 5.Subjects having plaque index scores equals to 2 and in more than 10% of the sites. 6.Subjects with no history of hypersensitivity reactions. 7. Able to communicate adequately with the investigator and to comply with the requirements for the entire study. 8. Subjects should not have history of periodontal therapy one month prior to screening. 9. Patient should be able to give written informed consent prior to participating in the study.
Exclusion criteria
Exclusion criteria: Subjects who have used antibiotics, antimicrobials, steroidal anti- inflammatory drugs, desensitizing toothpaste and NSAIDs within one month prior to screening. 2. Concomitant diseases (i.e. cancer, kidney diseases, liver diseases, neurological diseases, psychiatric diseases, blood disorders, gastrointestinal diseases). 3. Subjects with systemic conditions like diabetes, gastritis; oral diseases such as advanced periodontitis, frank dental caries, mucosal lesions. 4. Subjects with history of smoking or chewing tobacco. 5. Subjects with orthodontic appliances. 6. Hypersensitivity to any components of the investigational product. 7. Pregnancy and breastfeeding women. 8. Participation in concomitant interventional clinical study during the previous 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Reduction of Modified gingival Index. 2. Reduction of Plaque Index.Timepoint: Screening week 4, 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Reduction of cariogenic oral microflora. 2.In achieveing a significant reduction in CFUs in gram positive. 3.In achieveing a significant reduction in CFUs in gram negative. 4.Improvement of clinical oral dryness score (CODS). 5.Enhancement of organoleptic scoring scale (OSS). 6.Improvement VITA shade scale. 7.Compliance and tolerability. 8.Overall treatment satisfaction questionnaire.Timepoint: Baseline week 4, 8 | — |
Countries
India
Contacts
Syncretic Clinical Research Services Pvt. Ltd.